Johnson County Clin-Trials
Lenexa, Kansas, 66219, United States
NCT Number: NCT00706732
The objective of this study is to evaluate the safety of the vaccine and the immune response to the vaccine in healthy adult volunteers 65 years of age or older. Volunteers will be assigned by randomization to receive either the vaccine or an inactive substance (placebo) by injections in the arm on two occasions over one month. The study will last approximately 10 months and will have a total of 7 visits.
Looking for future studies?
Notify Me65 year and older
All sexes
Interventional
Phase 1 / Phase 2
Lenexa, Kansas, 66219, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
2 doses at 2e8 IU given at T=0 and T=4 weeks via the IM route
2 doses of placebo given at T=0 and T=4 weeks via the IM route
Time frame: 28 weeks
Time frame: 4 weeks after second dose of vaccine
AlphaVax, Inc.
Industry
A Single-Site, Phase I/II, Double Blinded, Safety and Immunogenicity Trial of an Alphavirus Replicon Vaccine Expressing Influenza A/Wyoming/03/2003 Hemagglutinin (AVX502) in Adult Volunteers 65 Years of Age or Older
Acronym: AVX502-003
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04794829
COVID-19, Coronaviridae Infections
Bethesda, Maryland, United States
View Trial DetailsNCT07737106
Infections, Influenza
Bayan Nur, Inner Mongolia, China
View Trial DetailsNCT06518577
Infections, Influenza
Phoenix, Arizona, United States
View Trial DetailsNCT06560151
Infections, Influenza
Atlanta, Georgia, United States
View Trial Details